TY - JOUR
T1 - Apraclonidine and Anterior Segment Laser Surgery
T2 - Comparison of 0.5% versus 1.0% Apraclonidine for Prevention of Postoperative Intraocular Pressure Rise
AU - Rosenberg, Lisa F.
AU - Krupin, Theodore
AU - Ruderman, Jon
AU - McDaniel, D. Lee
AU - Siegfried, Carla
AU - Karalekas, Diane P.
AU - Grewal, Roopinder K.
AU - Gieser, David K.
AU - Williams, Ruth
N1 - Funding Information:
Supported in part by an unrestricted grant to the Department of Ophthalmology, Northwestern University Medical School, Chicago, Illinois, and from Research to Prevent Blindness. Inc, New York. New York. None of the authors have proprietay interests in apraclonidine. Reprint requests to Lisa F. Rosenberg, MD, 300 East Superior St, Tarry 5-715, Chicago, IL 60611.
PY - 1995
Y1 - 1995
N2 - Purpose: To compare the efficacy of 0.5% and 1.0% apraclonidine in preventing laser-induced intraocular pressure (IOP) elevation after trabeculoplasty, neodymium: YAG (Nd:YAG) iridotomy, and capsulotomy. Methods: This is a prospective, masked, and randomized study of 83 patients undergoing trabeculoplasty, 62 patients undergoing iridotomy, and 57 patients undergoing capsulotomy. Surgical eyes received one drop of 0.5% or 1.0% apraclonidine immediately after surgery. Results: Intraocular pressure reduced 2 hours after trabeculoplasty in the 0.5% (P = 0.028) and 1.0% (P = 0.004) groups. Intraocular pressure was higher than baseline in a greater number of eyes treated with 0.5% (12 of 39 eyes, 31%) compared with 1.0% apraclonidine (5 of 44 eyes, 11 %) (P = 0.032). Intraocular pressure in eyes with a narrow chamber angle was reduced in 16 (85%) of 19 eyes treated with 0.5% and in 10 (84%) of 12 eyes treated with 1.0% apraclonidine after iridotomy. Of patients with chronic angle-closure glaucoma, IOP was similar to prelaser values in 11 (69%) of 16 eyes treated with 0.5% (P > 0.7) and 12 (80%) of 15 eyes treated with 1.0% apraclonidine (P > 0.3). In patients undergoing capsulotomy, pressure was significantly lowered in the 0.5% group (P = 0.04) but not in the 1.0% apraclonidine group. After capsulotomy, both treatment groups had similar (P > 0.3) numbers of eyes with an IOP less than baseline (83% for 0.5% apraclonidine and 81% for 1.0% apraclonidine). Conclusion: The single postoperative administration of 0.5% apraclonidine is as effective as the 1.0% concentration in preventing IOP elevation immediately after trabeculoplasty, iridotomy, or capsulotomy.
AB - Purpose: To compare the efficacy of 0.5% and 1.0% apraclonidine in preventing laser-induced intraocular pressure (IOP) elevation after trabeculoplasty, neodymium: YAG (Nd:YAG) iridotomy, and capsulotomy. Methods: This is a prospective, masked, and randomized study of 83 patients undergoing trabeculoplasty, 62 patients undergoing iridotomy, and 57 patients undergoing capsulotomy. Surgical eyes received one drop of 0.5% or 1.0% apraclonidine immediately after surgery. Results: Intraocular pressure reduced 2 hours after trabeculoplasty in the 0.5% (P = 0.028) and 1.0% (P = 0.004) groups. Intraocular pressure was higher than baseline in a greater number of eyes treated with 0.5% (12 of 39 eyes, 31%) compared with 1.0% apraclonidine (5 of 44 eyes, 11 %) (P = 0.032). Intraocular pressure in eyes with a narrow chamber angle was reduced in 16 (85%) of 19 eyes treated with 0.5% and in 10 (84%) of 12 eyes treated with 1.0% apraclonidine after iridotomy. Of patients with chronic angle-closure glaucoma, IOP was similar to prelaser values in 11 (69%) of 16 eyes treated with 0.5% (P > 0.7) and 12 (80%) of 15 eyes treated with 1.0% apraclonidine (P > 0.3). In patients undergoing capsulotomy, pressure was significantly lowered in the 0.5% group (P = 0.04) but not in the 1.0% apraclonidine group. After capsulotomy, both treatment groups had similar (P > 0.3) numbers of eyes with an IOP less than baseline (83% for 0.5% apraclonidine and 81% for 1.0% apraclonidine). Conclusion: The single postoperative administration of 0.5% apraclonidine is as effective as the 1.0% concentration in preventing IOP elevation immediately after trabeculoplasty, iridotomy, or capsulotomy.
UR - http://www.scopus.com/inward/record.url?scp=0029101045&partnerID=8YFLogxK
U2 - 10.1016/S0161-6420(95)30869-X
DO - 10.1016/S0161-6420(95)30869-X
M3 - Article
C2 - 9097768
AN - SCOPUS:0029101045
SN - 0161-6420
VL - 102
SP - 1312
EP - 1318
JO - Ophthalmology
JF - Ophthalmology
IS - 9
ER -